Impact of IDO1 and IDO2 on the B Cell Immune Response.
| Autor: | Merlo LMF; Lankenau Institute for Medical Research, Wynnewood, PA, United States., Peng W; Lankenau Institute for Medical Research, Wynnewood, PA, United States., Mandik-Nayak L; Lankenau Institute for Medical Research, Wynnewood, PA, United States. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in immunology [Front Immunol] 2022 Apr 13; Vol. 13, pp. 886225. Date of Electronic Publication: 2022 Apr 13 (Print Publication: 2022). |
| DOI: | 10.3389/fimmu.2022.886225 |
| Abstrakt: | Indoleamine-2,3-dioxygenase (IDO)1 and IDO2 are closely related tryptophan catabolizing enzymes that have immunomodulatory properties. Although initially studied as modifiers of T cell activity, emerging evidence suggests IDO1 and IDO2 also have important roles as modulators of B cell function. In this context, IDO1 and IDO2 appear to play opposite roles, with IDO1 inhibiting and IDO2 driving inflammatory B cell responses. In this mini review, we discuss the evidence for IDO1 and IDO2 modulation of B cell function, focusing on the effect of these enzymes on autoimmunity, allergic responses, protective immunity, and response to pathogens. We summarize strategies to target IDO1 and/or IDO2 as potential therapeutics for inflammatory autoimmune disease and highlight outstanding questions and areas that require future study. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Merlo, Peng and Mandik-Nayak.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|